Evidence map›Paper›PMID 40193175›Full record

SynthesiseLife2025

Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents.

Ayni Sharif, Matthew S Jeffers, Dean A Fergusson, Raj Bapuji, Stuart G Nicholls, John Humphrey, Warren Johnston, Ed Mitchell, Mary-Ann Speirs, Laura Stronghill and 6 more

Registry-linked trialAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07080567 (Maraviroc for Stroke Recovery), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07080567 phase2recruitingnot on this map

Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial

TypeinterventionalSponsorEmmanuel CarreraRan2025 to 2027Enrolled80ConditionsIschemic Stroke, Stroke, Stroke AcuteArmsMaraviroc, Mannitol
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ayni Sharif *Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Matthew S Jeffers *Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.ORCID https://orcid.org/0000-0002-4148-2638
Dean A FergussonClinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Raj BapujiClinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Stuart G NichollsOffice for Patient Engagement in Research Activity (OPERA), Ottawa Hospital Research Institute, Ottawa, Canada.
John HumphreyPatient Partner, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Warren JohnstonPatient Partner, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Ed MitchellPatient Partner, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Mary-Ann SpeirsPatient Partner, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Laura StronghillPatient Partner, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Michele VuckovicPatient Partner, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Susan WulfPatient Partner, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Risa ShorrOttawa Hospital Library Services, The Ottawa Hospital, Ottawa, Canada.
Dar DowlatshahiSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
Dale CorbettDepartment of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Manoj M LaluClinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.ORCID https://orcid.org/0000-0002-0322-382X

Funding

Canadian Institutes of Health Research - Vanier Canada Graduate Scholarship CGV-186957University of Ottawa Social Accountability Grant
6 · The paper itself

Abstract

C-C chemokine receptor type 5 (CCR5) antagonists may improve both acute stroke outcome and long-term recovery. Despite their evaluation in ongoing clinical trials, gaps remain in the evidence supporting their use. With a panel of patients with lived experiences of stroke, we performed a systematic review of animal models of stroke that administered a CCR5 antagonist and assessed infarct size or behavioural outcomes. MEDLINE, Web of Science, and Embase were searched. Article screening and data extraction were completed in duplicate. We pooled outcomes using random effects meta-analyses. We assessed risk of bias using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool and alignment with the Stroke Treatment Academic Industry Roundtable (STAIR) and Stroke Recovery and Rehabilitation Roundtable (SRRR) recommendations. Five studies representing 10 experiments were included. CCR5 antagonists reduced infarct volume (standard mean difference -1.02; 95% confidence interval -1.58 to -0.46) when compared to stroke-only controls. Varied timing of CCR5 administration (pre- or post-stroke induction) produced similar benefit. CCR5 antagonists significantly improved 11 of 16 behavioural outcomes reported. High risk of bias was present in all studies and critical knowledge gaps in the preclinical evidence were identified using STAIR/SRRR. CCR5 antagonists demonstrate promise; however, rigorously designed preclinical studies that better align with STAIR/SRRR recommendations and downstream clinical trials are warranted. Prospective Register of Systematic Reviews (PROSPERO CRD42023393438).

Indexed as

CCR5 Receptor AntagonistsNeuroprotective AgentsStrokeAnimalsDisease Models, AnimalHumansReceptors, CCR5Recovery of FunctionCCR5 Receptor AntagonistsNeuroprotective AgentsReceptors, CCR5CCR5maravirocmedicinemouseneuroprotectionneurosciencepatient engagementpreclinicalratstroke

Identifiers

PMID40193175
PMCPMC11975378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.